Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Contenido archivado el 2024-06-18

Metagenomics in Cardiometabolic Diseases

Objetivo

METACARDIS applies a systems medicine multilevel approach to identify biological relationships between gut microbiota, assessed by metagenomics, and host genome expression regulation, which will improve understanding and innovative care of cardiometabolic diseases (CMD) and their comorbidities. CMD comprise metabolic (obesity, diabetes) and heart diseases characterized by a chronic evolution in ageing populations and costly treatments. Therapies require novel integrated approaches taking into account CMD natural evolution.

METACARDIS associates European leaders in metagenomics, who have been successful in establishing the structure of the human microbiome as part of the EU FP7 MetaHIT consortium, clinical and fundamental researchers, SME, patients associations and food companies to improve the understanding of pathophysiological mechanisms, prognosis and diagnosis of CMD.

We will use next-generation sequencing technologies and high throughput metabolomic platforms to identify gut microbiota- and metabolomic-derived biomarkers and targets associated with CMD risks. The pathophysiological role of these markers will be tested in both preclinical models and replication cohorts allowing the study of CMD progression in patients collected in three European clinical centres of excellence. Their impact on host gene transcription will be characterised in patients selected for typical features of CMD evolution. Application of computational models and visualisation tools to complex datasets combining clinical information, environmental patterns and gut microbiome, metabolome and transcriptome data is a central integrating component in the research, which will be driven by world leaders in metagenomic and functional genomic data analysis. These studies will identify novel molecular targets, biomarkers and predictors of CMD progression, paving the way for personalized medicine in CMD.

Ámbito científico

Programa(s)

Tema(s)

Convocatoria de propuestas

FP7-HEALTH-2012-INNOVATION-1
Consulte otros proyectos de esta convocatoria

Régimen de financiación

CP-IP - Large-scale integrating project

Coordinador

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Aportación de la UE
€ 2 562 788,00
Dirección
RUE DE TOLBIAC 101
75654 Paris
Francia

Ver en el mapa
Región
Ile-de-France Ile-de-France Paris
Tipo de actividad
Research Organisations
Contacto administrativo
Akouavi Ekoue (Ms.)
Enlaces
Coste total
Sin datos

Participantes (15)

Compartir esta página

Descargar

Última actualización: 6 Septiembre 2024

Mi folleto

Permalink: https://cordis.europa.eu/project/id/305312/es

European Union, 2024